BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 460,444 shares of the company’s stock after selling 525 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Johnson & Johnson were worth $76,360,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in JNJ. Brighton Jones LLC raised its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Hudson Value Partners LLC raised its holdings in shares of Johnson & Johnson by 2.5% in the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock worth $5,648,000 after purchasing an additional 1,022 shares during the period. Topsail Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at $369,000. Voya Financial Advisors Inc. raised its stake in shares of Johnson & Johnson by 6.0% in the fourth quarter. Voya Financial Advisors Inc. now owns 4,998 shares of the company’s stock valued at $716,000 after buying an additional 282 shares during the period. Finally, Cheviot Value Management LLC raised its stake in shares of Johnson & Johnson by 9.8% in the fourth quarter. Cheviot Value Management LLC now owns 155,318 shares of the company’s stock valued at $22,462,000 after buying an additional 13,823 shares during the period. 69.55% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
JNJ has been the topic of several research reports. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Guggenheim restated a “neutral” rating and issued a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Citigroup boosted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday. Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Wall Street Zen lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $176.29.
Johnson & Johnson Stock Up 0.1%
JNJ stock opened at $179.0980 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company’s 50 day moving average is $163.48 and its 200 day moving average is $159.23. The stock has a market cap of $431.33 billion, a price-to-earnings ratio of 19.15, a price-to-earnings-growth ratio of 2.28 and a beta of 0.41. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read More
- Five stocks we like better than Johnson & Johnson
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- MarketBeat Week in Review – 08/18 – 08/22
- Dividend Capture Strategy: What You Need to Know
- Royal Caribbean Earnings Beat Fuels Strong 2025 Outlook
- ESG Stocks, What Investors Should Know
- Alphabet’s Breakout Potential: From Laggard to AI Leader
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.